We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00743574
Recruitment Status : Completed
First Posted : August 29, 2008
Results First Posted : July 29, 2013
Last Update Posted : August 13, 2021
National Center for Research Resources (NCRR)
Information provided by (Responsible Party):
Yale University

Brief Summary:
The investigators conducted a prospective un-blinded pilot study of Vitamin D plus Calcium (Ca) supplementation in overweight (BMI > 27) premenopausal women diagnosed with Polycystic Ovarian Syndrome (PCOS), as defined by the Rotterdam Criteria, 2003, and who were deficient in vitamin D as reflected by serum 25-hydroxy (25-OH) vitamin D (serum levels < 20 ng/mL).

Condition or disease Intervention/treatment Phase
Polycystic Ovarian Syndrome Vitamin D Deficiency Dietary Supplement: Vitamin D2 (Ergocalciferol) Drug: Medroxyprogesterone (Provera) Dietary Supplement: Vitamin D3 (Cholecalciferol) Dietary Supplement: Elemental Calcium Not Applicable

Detailed Description:

We had hypothesized that in women with PCOS, administering optimal daily doses of vitamin D3, as recommended by the National Academy of Sciences, 2000IU Cholecalciferol and 1000mg of calcium, both per oral (PO), over a three month period will improve their metabolic picture, and possibly hormone profile.

Over the course of the trial, after the first 5 subjects had completed 3 month intervention,we observed that daily 2000IU D3 dosing regime was inadequate in normalizing vitamin D status in the study population; the dosing regimen was therefore modified to include weekly supplementation with 50,000IU D2 in addition to daily dosing with 2000IU D3.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)
Study Start Date : August 2008
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Experimental: Vitamin D plus Calcium (Ca) supplementation Dietary Supplement: Vitamin D2 (Ergocalciferol)
50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)

Drug: Medroxyprogesterone (Provera)
10mg, PO, daily for ten days

Dietary Supplement: Vitamin D3 (Cholecalciferol)
2,000IU (or 2 tablets), PO, daily (supplements taken for three months)

Dietary Supplement: Elemental Calcium
1,000mg (or 2 tablets), PO, daily (supplements taken for three months)

Primary Outcome Measures :
  1. Serum HbA1C at 3 Months [ Time Frame: Completion ]
    Fasting HbA1C levels at study completion after 3 month treatment

  2. Fasting Insulin Levels at Study Completion After 3 Month Treatment [ Time Frame: 3 months intervention ]
    Fasting insulin levels at study completion after 3 month treatment

  3. Fasting Glucose Levels at Completion of Treatment, at 3 Months [ Time Frame: 3 months ]
    Fasting glucose levels drawn after 3 months completion during oral GTT

  4. AUC (Area Under a Curve at 0, 0.5, 1, 1.5 and 2 Hours) Insulin During 2 Hour GTT at Completion, at 3 Months [ Time Frame: 3 months ]
    Following 3 months intervention, AUC insulin was determined during 2 hour oral GTT

  5. AUC (Area Under the Curve at 0, 0.5, 1, 1.5 and 2 Hours) During Oral GTT at Completion, at 3 Months [ Time Frame: 3 months ]
    AUC (Area under the curve at 0, 0.5, 1, 1.5 and 2 hours)for glucose was determined at completion of 3 months intervention for 2 hour oral GTT

Secondary Outcome Measures :
  1. Serum Levels of C-reactive Protein at Completion of 3 Months Treatment [ Time Frame: 3 months ]
    Serum levels of C-reactive protein upon completion, at 3 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Premenopausal women (ages 18-40 years) with normal thyroid function and prolactin levels.
  • PCOS diagnosis based on Rotterdam criteria: presence of at least 2 of the following criteria:

    • oligomenorrhea-menstrual cycles > 35 day intervals
    • hyperandrogenemia (elevated serum testosterone [free or total] &/or androstenedione levels) or features of hyperandrogenism i.e. acne or hirsuitism [Ferriman-Gallaway score > 3]
    • polycystic ovaries on vaginal ultrasound as defined by ESHRE/ASRM criteria (ovarian volume ≥ 10mL or ≥ 12 follicles of diameter between 2-9mm in at least one ovary)
    • Overweight (BMI ≥ 27 Kg/m2)
    • Biochemical evidence of Vitamin D insufficiency (i.e. serum 25 OHD levels < 20ng/mL)

Exclusion Criteria:

  • Pregnancy
  • Known causes of oligomenorrhea other than PCOS, e.g. hypothyroidism/Cushing's Disease/late onset congenital adrenal hyperplasia (fasting 17-alphahydroxyprogesterone levels < 200ng/dL)
  • Use of hormonal treatment (birth control pill/patch/depot medroxyprogesterone/medroxyprogesterone) within 3 months of the study onset.
  • Use insulin sensitizers (metformin, sulfonylureas, TZDs, incretins) within 3 months of the study onset.
  • Use of lipid lowering agents or medications known to influence insulin sensitivity (e.g. niacin, corticosteroids, beta blockers, calcium channel blockers, thiazide diuretics) or influence serum androgens (estrogen, anti-androgens, androgens) within 3 months of the study onset.
  • Known history of renal calculi or current use of Calcium and Vitamin D supplements.
  • Spanish Speaking.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00743574

Layout table for location information
United States, Connecticut
Yale-New Haven Hospital-Women's Center
New Haven, Connecticut, United States, 06520-8063
Sponsors and Collaborators
Yale University
National Center for Research Resources (NCRR)
Layout table for investigator information
Principal Investigator: Lubna Pal, MBBS,MRCOG,MSc. Yale University
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00743574    
Other Study ID Numbers: YaleU-0807003992
YCCI-CARE Grant #UL1RR024139
First Posted: August 29, 2008    Key Record Dates
Results First Posted: July 29, 2013
Last Update Posted: August 13, 2021
Last Verified: August 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Vitamin D Deficiency
Pathologic Processes
Deficiency Diseases
Nutrition Disorders
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Vitamin D
Medroxyprogesterone Acetate
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents
Contraceptives, Oral, Hormonal
Contraceptives, Oral
Contraceptive Agents, Female